Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-03
2009-10-13
Yaen, Christopher H (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07601697
ABSTRACT:
Compounds and compositions for eliciting or enhancing immune reactivity to HER-2
eu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2
eu oncogene is associated.
REFERENCES:
patent: 3766162 (1973-10-01), Spector
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4233402 (1980-11-01), Maggio et al.
patent: 4452901 (1984-06-01), Gordon et al.
patent: 5320947 (1994-06-01), Cheever et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5693522 (1997-12-01), Chada et al.
patent: 5958784 (1999-09-01), Benner
patent: 5985553 (1999-11-01), King et al.
patent: 6953573 (2005-10-01), Cheever et al.
patent: WO 90/14357 (1990-11-01), None
patent: WO 91/02062 (1991-02-01), None
Alper et al., “The Presence of c-erbB-2 Gene Product-related Protein in Culture Medium Conditioned by Breast Cancer Cell Line SK-BR-3,”Cell Growth&Differentiation 1:591-599, 1990.
Bargmann et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein,”Nature 319:226-230, 1986.
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185(^HER2) Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer,”Journal of Clinical Oncology 14(3): 737-744, 1996.
Ben-Mahrez et al., “Circulating Antibodies Against C-myc Oncogene Product In Sera Of Colorectal Cancer Patients,”Int. J. Cancer 46: 35-38, 1990.
Ben-Mahrez et al., “Detectopm of circulating antibodies against c-myc protein in cancer patient sera,”British J. Cancer 57: 529-534, 1988.
Bishop and Orosz, “Limiting Dilution Analysis For Alloreactive, TCGF-Secretory T Cells. Two Related LDA Methods That Discriminate Between Unstimulated Precursor T Cells and In Vivo-Alloactivated T Cells,”Transplantation 47(4): 671-677, 1989.
Bodmer, W., “T-Cell Immune Responses to Cancer—A New Look,”Human Immunology 30:259-261, 1991.
Bowen-Pope et al., “Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents,”Proc. Natl. Acad. Sci. USA 81: 2396-2400, 1984.
Brooks et al., “Human lymphocyte markers defined by antibodies derived from somatic cell hybrids,”Clin. Exp. Immunol. 39: 477-485, 1980.
Brown et al., “Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies,”Journal of Biological Chemistry 255(11): 4980-4983, 1980.
Burnette et al., “Western Blotting: Electropheretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A,”Analytical Biochemistry 112: 195-203, 1981.
Coussens et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene,”Science 230: 1132-1139, 1985.
Crystal, R.G., “In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors,”Cancer Chemother. Pharmacol. 43(Suppl): S90-S99, 1999.
Davis, H.L. et al., “Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression,”Human Gene Therapy 4: 151-159, 1993.
Dhut et al, “BCR-ABL and BCR Proteins: Biochemical Characterization and Localization,”Leukemia 4(11): 745-750, 1990.
Disis et al., “Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients With Breast Cancer,”Cancer Res. 54: 16-20, 1994.
Eck and Wilson, “Gene-based therapy,” inGoodman&Gilman 's The Pharmacological Basis of Therapeutics, 9thedition, McGraw-Hill, New York, 1996, pp. 77-101.
Falk et al., “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,”Nature 351: 290-296, 1991.
Feller and de la Cruz, “Identifying antigenic T-cell sites,”Nature 349: 720-721, 1991.
Fisk et al., “Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro,”Cellular Immunology 157:415-427, 1994.
Flanagan and Leder, “neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation,”Proc. Natl. Acad. Sci. USA 85: 8057-8061, 1998.
“Gene Therapy,” www.gateway.nlm.nih.gov. visted Jan. 23, 2004.
Igelhart et al., “Increased erbB-2 Gene Copies and Expression in Multiple Stages of Breast Cancer,”Cancer Research 50: 6701-6707, 1990.
Ioannides et al., “Antigens Recognized by T cells in Ovarian Cancer,” in Abstracts of the Fourth International Conference of Anticancer Research, Oct. 21-25, 1992, Rethymnon, Crete, Greece, p. 1870.
Ioannides et al., “CTL Clones Isolated from Ovarian Tumor Infiltrating Lymphocytes can Recognize Peptides with Sequences Corresponding to the HER2
eu Gene Product,”FASEB Journal 6: A1404, Abstract No. 2711, 1992.
Ioannides et al., “Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene,”Cell. Immunol. 151: 225-234, 1993.
Ioannides et al., “Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones,”Scand. J. Immunol. 37: 413-424, 1993.
Ioannides et al., “T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy,”Molecular Carcinogenesis 6: 77-82, 1992.
Ioannides, “Antigens and vaccines of female genital cancers (Meeting abstract),” Cancerlit Database Abstract No. ICDB/93690682, 1992.
Ioannides, et al., “Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene,”Cell. Immunol. 151:225-234, 1993.
Kallioniemi et al., “ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization,”Proc. Natl. Acad. Sci. 89: 5321-5325, 1992.
Kerns et al., “c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry,”Journal of Histochemistry and Cytochemistry 38(12): 1823-1830, 1990.
Laemmli, U., “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4,”Nature 227: 680-685, 1970.
Leitzel et al., “Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients,”Journal of Clinical Oncology 10(9): 1436-1443, 1992.
Lichtenstein et al., “Effects of .beta.-2 Microglobulin Anti-sense oligonucleotides on Sensitivity of HER2
eu Oncogene-Expressing and Nonexpressing Target Cells to Lymphocyte-Mediated Lysis,”Cellular Immunology 141: 219-232, 1992.
Lippman, M., “Potential Contributions of Breast Cancer Biology to Management of Breast Cancer,”Advances in Oncology 8(3): 26-28, 1992.
Lippman, M., “Potential Contributions of Breast Cancer Biology to Management of Breast Cancer”,Advances in Oncology 8(3): 26-28, 1992.
Maguire and Greene, “The neu (c-erbB-2) Oncogene,”Seminars in Oncology 16(2): 148-155, 1989.
Margalit et al., “Prediction Of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence,”Journal of Immunology 138(7): 2213-2229, 1987.
McGlynn et al., “Large-scale purification and characterisation of a recombinant epid
Cheever Martin A
Disis Mary L
Seed IP Law Group PLLC
University of Washington
Yaen Christopher H
LandOfFree
Compounds for eliciting or enhancing immune reactivity to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for eliciting or enhancing immune reactivity to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for eliciting or enhancing immune reactivity to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098275